Who
Linda Grais
Director
Company insider
Files Form 4 as: Director, Icon; Director, Corvus Pharmaceuticals; Director, Oruka Therapeutics; Director, PRA Health Sciences; Director, Zosano Pharma; President and CEO, Ocera Therapeutics.
In numbers
- Trades disclosed
- 85
- Buys
- 7
- Sells
- 2
- Bought
- $265K
- Sold
- $1.8M
- Companies
- 6
- Companies where not an officer
- 5
- First trade
- 27 Feb 2009
- Last trade
- 11 Aug 2026
- Last filed
- 12 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Aug 2026filed 12 Aug 2026 | ICLR IconLife-science tools | SEC FORM 4 Sold | $14K87 at $162.72 | filing |
| 11 Aug 2026filed 12 Aug 2026 | ICLR IconLife-science tools | SEC FORM 4 Sold | $16K97 at $163.77 | filing |
| 11 Aug 2026filed 12 Aug 2026 | ICLR IconLife-science tools | SEC FORM 4 Sold | $97K590 at $164.47 | filing |
| 11 Aug 2026filed 12 Aug 2026 | ICLR IconLife-science tools | SEC FORM 4 Sold | $11K67 at $165.51 | filing |
| 11 Aug 2026filed 12 Aug 2026 | ICLR IconLife-science tools | SEC FORM 4 Sold | $14K87 at $162.72 | filing |
| 11 Aug 2026filed 12 Aug 2026 | ICLR IconLife-science tools | SEC FORM 4 Sold | $16K97 at $163.77 | filing |
| 11 Aug 2026filed 12 Aug 2026 | ICLR IconLife-science tools | SEC FORM 4 Sold | $97K590 at $164.47 | filing |
| 11 Aug 2026filed 12 Aug 2026 | ICLR IconLife-science tools | SEC FORM 4 Sold | $11K67 at $165.51 | filing |
| 10 Aug 2026filed 12 Aug 2026 | ICLR IconLife-science tools | SEC FORM 4 Code M | —1,732 | filing |
| 10 Aug 2026filed 12 Aug 2026 | ICLR Iconoption or derivative · Life-science tools | SEC FORM 4 Code M | —1,732 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | ICLR Iconoption or derivative · Life-science tools | SEC FORM 4 Code A | —1,324 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | ICLR Iconoption or derivative · Life-science tools | SEC FORM 4 Code M | —1,732 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | ICLR Iconoption or derivative · Life-science tools | SEC FORM 4 Code A | —1,324 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | ICLR IconLife-science tools | SEC FORM 4 Code M | —1,732 | filing |
| 11 Jun 2026filed 15 Jun 2026 | CRVS Corvus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | CRVS Corvus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | CRVS Corvus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 13 Jun 2024filed 17 Jun 2024 | CRVS Corvus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 30 Jan 2024filed 31 Jan 2024 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 6 Dec 2023filed 8 Dec 2023 | CRVS Corvus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
News
Head to Head Review: CryoPort (NASDAQ:CYRX) and Icon (NASDAQ:ICLR)ICLR · themarketsdaily.com · 20 Oct 2026
0 headlines in the last 90 days name Linda Grais; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.